Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications
Cynthia W. Tuthill Robert S. King
Research Article — Peer-Reviewed Source
Original research published by King et al. in Clinical and Experimental Pharmacology. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Thymosin alpha 1 (thymalfasin, Ta1), the active ingredient in ZADAXIN , is a peptidic biological response modifier which activates various cells of the immune system. Ta1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective, such as acute and chronic infections, cancers, and vaccine non-responsiveness, all of which are hallmarks of an impaired or inadequate immune response. Importantly, Ta1 acts without overstimulation of cytokine production and is generally well tolerated; it has an excellent safety profile and does not appear to induce the side effects and toxicities commonly associated with agents in this class such as interferonalpha and interleukin-2.
Full text is available at the publisher.
Read at Publisher| DOI | 10.4172/2161-1459.1000133 |
| Journal | Clinical and Experimental Pharmacology |
| Year | 2013 |
| Authors | Cynthia W. Tuthill Robert S. King |
| License | Open Access — see publisher for license terms |
| Citations | 24 |